Japan's Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds - Reuters

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNaFJSSWFEbGxOWjZyYm1GOVVNWXUtRXBMSnlYXzU5U3BDMlc1ZEpjS1cwbnFoVDR2WHBnQUJGVDU3LVFQRUJkQ2FabWpvSmk0NFFyemtNT3pFY1gzQWlRSzNKbkZSZXdxcWNac3hsel92TjhrN1Ffc0Vld2s2NVBWOWppbEZDTk5oX2lOT1l2eGlLQUxKQWRfeGJmc25ja2FjWGtwcDNVLWhleU0zUDNPRVA0NW5lUWNqZG9r?oc=5" target="_blank">Japan's Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

A U.S. jury found Takeda Pharmaceutical liable for causing about $885 million in damages by delaying a generic version of its constipation drug Amitiza through an anticompetitive scheme.

A Boston jury found Takeda Pharmaceutical responsible for $885 million in damages, ruling they delayed a generic version of Amitiza through an anticompetitive scheme. This marks the first such jury verdict since 2013.

A federal jury ordered Takeda Pharmaceuticals Co. Ltd. to pay $884.9 million in damages for violating antitrust law by delaying the generic version of its branded Amitiza drug through an illegal agreement with a competitor.

A Boston federal jury found Takeda Pharmaceuticals conspired with a generic drugmaker to delay the launch of a generic version of Takeda's anticonstipation drug, awarding purchasers $885 million, a figure that's expected to swell after a rule tripling plaintiffs' antitrust damages is applied.

A class-action lawsuit against Takeda Pharmaceuticals USA Inc. on behalf of direct purchasers of Amitiza and its generic equivalents ended today when a jury returned a verdict finding the pharma giant liable for $474.89 million in damages, according to attorneys at Hagens Berman.